Introduction
============

Tuberculosis (TB) is a serious infection disease in developing countries, which is caused by the pathogen *Mycobacterium tuberculosis* (Mtb) ([@ref-8]). To date, the major strategies against tuberculosis are comprehensive chemotherapeutic regimens. However, with the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB), it becomes more difficult to fight against tuberculosis by chemotherapy alone. In addition to acquired drug resistance ([@ref-29]), intrinsic drug resistance has been proven to exist in *Mycobacterium tuberculosis* ([@ref-6]), in which active drug efflux pumps play important roles ([@ref-10]; [@ref-33]).

Since Mtb is an intracellular pathogen living in macrophages, more and more evidence suggested the important role of cellular immunity in controlling its dissemination. It has been proven that, in addition to CD4^+^ T cells, MHC class I restricted CD8^+^ T cells also play very important roles in immune responses against Mtb. The role of CD8^+^ T cell-mediated cellular immunity was extensively described in Mtb-challenged mouse models, non-human primates, as well as patients ([@ref-5]; [@ref-11]; [@ref-12]; [@ref-19]; [@ref-32]).

Although a lot of work has been done to develop new vaccines, BCG is the only approved one against tuberculosis, while its efficacy in adults has been questioned ([@ref-1]). Considering all these reasons mentioned above, we believed that it would be very worthy to identify HLA-A2 restricted cytotoxic T lymphocyte (CTL) epitopes derived from drug efflux pump antigens of Mtb. It would help us to develop effective subunit vaccines against TB, especially XDR and MDR strains caused by over-expression of the efflux pumps.

Classical ABC (ATP binding cassette) family is the most well-known efflux pump family which is responsible for intrinsic drug resistance. It was shown that the over-expression of Rv2686c-Rv2687c-Rv2688c in *M. smegmatis* increased the minimum inhibitory concentrations of ciprofloxacin ([@ref-27]). Rv2937 (drrB) together with drrA behaved as a functional efflux pump referring to drug resistance of rifampin, tetracycline and erythromycin ([@ref-4]). Because of that, both drrA and Rv2688c have significant homology with some proteins in human, Rv2937, Rv2686c, and Rv2687c were chosen as target antigens to identify HLA-A2 restricted cytotoxic T lymphocyte epitopes.

Eight potential peptides derived from Rv2937, Rv2686c, and Rv2687c were predicted by using the online tools, SYFPEITHI, BIMAS, and NetCTL. These peptides were synthesized, and their ability to induce immune response was tested in PBMCs of HLA-A2^+^ donors (*in vitro*) and HLA-A2/K^b^ transgenic mice (*in vivo*).

Materials and Methods
=====================

Prediction and synthesis of candidate peptides
----------------------------------------------

By using epitope prediction tools, BIMAS (<http://bimas.dcrt.nih.gov/molbio/hla_bind/>) ([@ref-26]), SYFPEITHI (<http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm>) ([@ref-30]), and NetCTL (<http://www.cbs.dtu.dk/services/NetCTL/>) ([@ref-18]), potential HLA-A2-restricted T cell epitopes derived from Rv2937, Rv2686c, and Rv2687c were predicted. Peptides with relative high scores were synthesized by standard solid phase Fmoc strategy. The peptides were purified by reverse phase-high performance liquid chromatography (RP-HPLC), and their molecular weights were confirmed by electrospray ionization-mass spectrometry (ESI-MS). The peptide HBcAg~18--27~ (FLPSDFFPSV) was used as irrelevant negative control, and the HBV core antigen-derived T helper epitope (sequence128--140: TPPAYRPPNAPIL) was used to enhance the immune activity in the mice immunization experiment ([@ref-23]; [@ref-36]).

Blood samples, animals and cell lines
-------------------------------------

Whole blood samples were prepared from HLA-A2^+^ (PPD^+^ or PPD^−^) healthy donors. The HLA-A2.1/K^b^ transgenic mice were previously gifted by Professor Xue-tao Cao (Second Military Medical University) ([@ref-37]). All mice at 8 to 12 weeks in the experiments were housed in a specific pathogen-free environment in our laboratory. The sample collection from healthy donors and animal experiments were approved by the Ethics Committee of Zhengzhou University (No. 20120312). The human transporter associated with antigen processing (TAP) -deficient T2 cell line was kindly provided by professor Yu-zhang Wu (Third Military Medical University, China), and the cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and maintained at 37 °C in an incubator with a humidified atmosphere containing 5% CO~2~.

Generation of CTLs from PBMCs of HLA-A2^+^ donors
-------------------------------------------------

The procedure of generation of CTLs *in vitro* was performed in accordance with the protocols described by our laboratory ([@ref-20]; [@ref-31]). Briefly, PBMCs were isolated from six HLA-A2^+^ PPD^+^ and an HLA-A2^+^ PPD^−^ healthy donors with centrifugation at a Ficoll-Paque density gradient and then cultured in IMDM medium supplemented with 10% FBS, 100 units/mL penicillin, and 100 µg/ml streptomycin under the condition of 37 °C, 5% CO~2~ ([@ref-14]). Then, these cells were stimulated once a week with each candidate peptide (10 µg/ml) in the presence of 3 µg/ml *β*2-microglobulin. Human recombinant IL-2 (50 U/ml) and IL-7 (50 U/ml) were added both on day 3 and one day after each stimulation. Seven days after the third round of stimulation, the cytotoxic assay and ELISPOT assay were performed.

Generation of CTLs from HLA-A2.1/K^b^ transgenic mice
-----------------------------------------------------

CTLs from HLA-A2.1/K^b^ transgenic mice were generated as previously described ([@ref-20]; [@ref-31]). Briefly, HLA-A2.1/K^b^ transgenic mice were grouped randomly, and injected subcutaneously at the base of the tail with 100 µg each peptide emulsified in incomplete Freund's adjuvant (IFA) in the presence of 140 µg of the T helper epitope every five days ([@ref-9]; [@ref-35]). On day 11, spleen lymphocytes of each mouse were separated and then re-stimulated with the corresponding peptide (10 µg/ml) *in vitro* for another five days. Then, the LDH cytotoxicity and ELISPOT assays were employed.

ELISPOT assay
-------------

ELISPOT assay was performed according to the instruction of the commercial kit (Dakewe Biotech Company, Shenzen, China). Peptide-pulsed T2 cells (stimulator cells, 1 × 10^5^), along with the induced CTLs (effector cells, 1 × 10^5^), were seeded into an anti-human (or anti-mouse) IFN-*γ* antibody coated 96-well plate ([@ref-7]). After incubation for 16 h at 37 °C, cells were removed and plates were processed. Spots were counted with a computer-assisted spot analyzer (Dakewe Biotech Company, Shenzen, China).

Cytotoxicity assay
------------------

Cytotoxic activity was tested by the non-radioactive cytotoxicity assay kit (Promega, US) at gradient E:T ratio according to the manufacturer's instruction. T2 cells were loaded with 10 µg/ml peptide for 1 h at 37 °C as target cells. The effector cells were co-cultured with target cells (1 × 10^4^ cells/well) at various effector/target ratios for 5 h at 37 °C under 5% CO~2~. The percentage of specific lysis of the target cells was determined according to the following formula. Percentage of specific lysis = \[(experimental release − effector spontaneous release − target spontaneous release)/(target maximum release − target spontaneous release)\] × 100.

Statistical analysis
--------------------

All data were presented as means ± SD. Comparisons between experimental groups and relevant controls were analyzed by Student's *t* test. *P* \< 0.05 was considered as statistically significant difference.

Results
=======

Peptides selected as potential CTL epitopes
-------------------------------------------

By using the on-line prediction tools, eight potential HLA-A2 restricted CTL epitopes were selected from the three candidate efflux pump antigens: Rv2937, Rv2686c, and Rv2687c. These peptides were synthesized and their molecular weights were confirmed by ESI-MS. ([Table 1](#table-1){ref-type="table"}).
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###### The data of ESI-MS and prediction of HLA-A2 restricted epitopes from efflux pumps of *Mycobacterium tuberculosis*.

![](peerj-03-1229-g005)

  Antigen   Position    Sequence    Scores    ESI-MS \[M+H/Na\]^+^                     
  --------- ----------- ----------- --------- ---------------------- -------- -------- --------
  Rv2937    168         YIVGFCLLV   167.168   24                     1.2629   1026.3   1026.7
  262       VMAPTLTWL   331.788     27        1.2098                 1031.3   1031.7   
  266       TLTWLFAFV   726.818     22        1.1149                 1097.3   1097.7   
  Rv2686c   151         GLVAGLSAV   159.970   28                     0.9644   786.0    786.7
  181       ALGMLIAGL   49.134      30        0.9898                 858.1    858.7    
  184       MLIAGLPCL   83.527      29        1.3358                 930.2    930.6    
  Rv2687c   89          YLAAKLTVL   92.666    29                     1.3019   991.2    991.8
  151       FLAAVIPLA   52.561      22        1.2362                 914.2    914.6    

IFN-*γ* release ELISPOT assay *in vitro*
----------------------------------------

CTLs were induced from the PBMCs of six HLA − A2^+^ PPD^+^ and an HLA − A2^+^ PPD^−^ healthy donors. IFN-*γ* release ELISPOT assay was employed to test the capacity of the eight peptides to induce CTL response. As shown in [Fig. 1A](#fig-1){ref-type="fig"}, Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184, but not the irrelevant peptide HBcAg~18--27~, could induce more frequent and potent CTL response in the six HLA-A2^+^ PPD^+^ donors, while all these peptides could only induce very weak response in the HLA-A2^+^ PPD^−^ donor ([Fig. 1B](#fig-1){ref-type="fig"}).

![IFN-*γ* release assay by ELISPOT.\
Efflux pumps derived peptides were used to induce CTLs from PBMCs of (A) six HLA-A2^+^ PPD^+^ donors, and (B) one HLA-A2^+^ PPD^−^ donor *in vitro*. T2 cells incubated with corresponding peptide and irrelevant peptide (50 µg/ml) for 4 h were used as stimulators. PBMCs from different donors were separated and stimulated with synthetic peptides and IL-2 in IMDM supplemented with 10% FCS for 21 days. Then, these PBMCs were collected, and ELISPOT assay was performed to determine the IFN-*γ* production by these cells. CTLs induced by PBS and irrelevant peptide HBcAg~18--27~ were taken as negative controls. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 represented the significances *vs* PBS group.](peerj-03-1229-g001){#fig-1}

*In vitro* cytotoxic activity of peptide-specific CTLs
------------------------------------------------------

Based on the results of the ELISPOT assay, Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 were selected to investigate whether the CTLs they induced could lyse target cells. In the cytotoxicity assay, PBMCs from HLA-A2^+^ PPD^+^ donor were stimulated with synthetic peptides according to the previously described method for CTLs induction, peptide-pulsed T2 cells were considered as target cells (HLA-A2^+^, antigen^+^). As shown in [Fig. 2](#fig-2){ref-type="fig"}, the specific lysis percentages of the CTLs induced by Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 from PBMCs of HLA-A2^+^ PPD^+^ healthy donor were increased along with the E/T ratio from 12.5:1 to 50:1. However, after incubating with anti-HLA-A2 monoclonal antibody, the specific lysis rates of the CTLs were greatly reduced. Meanwhile, CTLs induced by all these peptides in the HLA-A2^+^ PPD^−^ donor could not lyse the peptide-loaded T2 cells ([Fig. S1](#supp-1){ref-type="supplementary-material"}). These results indicated that these peptides could induce HLA-A2-restricted CTL response in PPD^+^ healthy donor.

![The cytotoxic activity of the CTLs induced by candidate peptides from human PBMCs.\
PBMCs from HLA-A2^+^ PPD^+^ donor were stimulated with each peptide (10 µg/mL) for three times. After 5 days of the final stimulation, the stimulated PBMCs were used as effector cells to detect their cytotoxic activity against target cells in LDH release assay. T2 cells loaded with peptide (HLA-A2^+^, antigen^+^), and T2 cells after which surface HLA-A2 molecules were blocked with anti-HLA-A2 monoclonal antibody (HLA-A2^−^, antigen^+^) were used as target cells. CTLs induced by PBS and irrelevant peptide HBcAg~18--27~ were taken as negative controls. (A--B) The effector cells were obtained from CTLs induced from PBMCs of HLA-A2^+^ PPD^+^ donors. (C) The HLA-A2 molecules on the T2 cells surface were blocked by anti-HLA-A2 monoclonal antibody. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 represented the significances *vs* PBS group.](peerj-03-1229-g002){#fig-2}

Cytotoxic T lymphocyte response in HLA-A2.1/K^b^ transgenic mice
----------------------------------------------------------------

HLA-A2.1/K^b^ transgenic mice immunization model has been widely used to study the *in vivo* CTL activity of HLA-A2-restricted epitopes. Since Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 could induce good immune response *in vitro*, we investigated whether these peptides could stimulate CTL response in HLA-A2.1/K^b^ transgenic mice. After immunization of each candidate peptide with Th epitope and IFA adjuvant, the spleen lymphocytes were isolated and stimulated with the corresponding peptide *in vitro* for another five days. IFN-*γ* release ELISPOT assay and LDH cytotoxicity assay were performed. As shown in [Fig. 3](#fig-3){ref-type="fig"}, all of the five peptides showed more potent activity to induce IFN-*γ* release than that of the Th control group.

![IFN-*γ* release ELISPOT assay of the spleen lymphocytes generated from immunized HLA-A2.1/K^b^ transgenic mice (*n* = 4).\
HLA-A2.1/K^b^ transgenic mice were immunized s.c with 100 µg each peptide emulsified in incomplete Freund's adjuvant (IFA) in the presence of 140 µg of the T helper epitope on day 0, 5, and 10. Mice injected with IFA containing PBS or T helper epitope were used as negative control. On day 11, the animals were sacrificed; spleen lymphocytes were re-stimulated *in vitro* by the relevant peptides for another five days. T2 cells incubated with relevant peptides (50 µg/mL) for 4 h were used as stimulators. Each sample was measured in three replicates. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 represented the significances *vs* Th epitope group.](peerj-03-1229-g003){#fig-3}

The cytotoxic activity of these spleen lymphocytes was also measured by LDH cytotoxicity assay. Peptide-loaded T2 cells were served as target cells and the effector/target ratios were 20:1, 40:1, and 80:1. As shown in [Fig. 4](#fig-4){ref-type="fig"}, at the E:T ratio of 80:1, the CTLs induced by Rv2937-p168, Rv2937-p266, Rv2686c-p151, and Rv2686c-p181 could significantly kill the target cells. To our surprise, although Rv2686c-p184 could induce the most potent IFN-*γ* release activity in PBMCs of HLA-A2^+^ PPD^+^ donors, it could not induce CTLs with killing effects in HLA-A2.1/K^b^ transgenic mice.

![Specific lysis of T2 cells loaded with synthetic peptides by the CTLs generated from the immunized HLA-A2.1/K^b^ transgenic mice (*n* = 4).\
HLA-A2.1/K^b^ transgenic mice were immunized as described above. T2 cells incubated with relevant peptides (50 µg/mL) for 4 h were used as target cells. Each sample was measured in three replicates. \**P* \< 0.05 represented the significances *vs* Th epitope group.](peerj-03-1229-g004){#fig-4}

Discussion
==========

Tuberculosis is considered to be a major public health concern worldwide because of its high morbidity and mortality rates. As reported, the emergence of XDR-TB and MDR-TB left patients with fewer options for treatment and at risk for higher mortalities, especially in HIV/TB co-infected patients ([@ref-28]). At present, BCG has been proven to be the only available vaccine for TB prevention, but it could not protect adults in most cases. One reason for this is the BCG defects in some important antigens. There are no effective therapeutic vaccines for TB patients as well, especially for the drug-resistant ones. Development of novel therapeutic vaccines provides a promising strategy to be combined with chemotherapy. Accumulating data showed that subunit vaccine containing peptide or protein antigens could exhibit protective activity with very good safety ([@ref-15]).

HLA-A2 is one of the most common supertypes of human leukocyte antigen particularly in Asian, with an estimated frequency of nearly 50% ([@ref-22]). Cellular immunity mediated by CD8^+^ T cells is believed important to control the latent Mtb infection. Therefore, identification of HLA-A2 restricted cytotoxic T lymphocyte epitopes derived from efflux pump antigens could be helpful to develop vaccines against drug-resistant TB caused by intrinsic drug efflux. Recently, most researchers who work on the identification of CTL epitopes of Mtb antigens focus their work on secretary proteins, such as ESAT-6 ([@ref-16]), 19-kDa lipoprotein ([@ref-25]), Ag85B ([@ref-13]), 16-kDa antigen ([@ref-2]), MPT51 ([@ref-34]), and so on. We also identified such kind of epitopes from CFP21 and RD region antigens ([@ref-3]; [@ref-21]). Furthermore, we first reported that efflux pumps could also be considered as target antigens for TB immunotherapy, and found that Rv1410c could serve as a candidate to the vaccine design against drug-resistant Mtb ([@ref-38]). We then screened classical efflux pump family members in the genome of TB to find more promising target antigens. As shown in the present study, we found that epitopes Rv2937-p168, Rv2937-p266, Rv2937-p168, Rv2686c-p181, and Rv2686c-p184 identified from ABC family members, could elicit good capacity to induce CTL response in HLA-A2^+^ PPD^+^ healthy donors and/or HLA-A2.1/K^b^ transgenic mice. Work still needs to be done to test whether infected macrophages could present the relevant peptides to CTLs, and to identify more promising antigens related to drug-resistant Mtb. We are now working on extrinsic drug-resistant antigens in Mtb. In the future, we hope we can combine all these epitopes derived from secretary and drug-resistant antigens to develop multi-valent subunit vaccines.

As is well known, early diagnosis of TB is fundamental for tuberculosis control. In the last decade, ELISPOT assay in the TB diagnosis is considered to have high specificity and sensitivity ([@ref-17]; [@ref-24]). Most of the five candidate peptides showed good activity among the six HLA-A2^+^ PPD^+^ healthy donors, but not in the HLA-A2^+^ PPD^−^ donor. Although we only tested the IFN-*γ* release assay in one HLA-A2^+^ PPD^−^ volunteer, and could not draw a conclusion from the results of our experiment, it is possible that these peptides have the potential to be used for TB diagnosis.

In the present study, we used so called 'reversal immunology' strategy to predict antigen epitopes by using on-line tools instead of time-consuming overlapping peptides method, which was proved to be very efficient. However, it may lead to large amounts of false positive and false negatives by using only one computational algorithm to predict CTL epitopes. Therefore, we used the epitope prediction tool NetCTL combined with the widely used BIMAS and SYFPEITHI databases. NetCTL integrates prediction of binding affinity, transporter of antigenic peptide efficiency and proteasomal cleavage ([@ref-18]), SYFPEITHI is a motif-matrix-based prediction method for MHC binding prediction ([@ref-30]) and BIMAS is based on peptide/MHC complex half-life ([@ref-26]). Our results suggested that this strategy could be very efficient and successful.

Conclusions
===========

In conclusion, we have identified five HLA-A2 restricted cytotoxic T lymphocyte epitopes derived from drug efflux pump antigens of *Mycobacterium tuberculosis*. The epitopes Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 showed moderate capacity to induce CTL response in HLA-A2^+^ PPD^+^ donors. Except for Rv2686c-p184, other epitopes could also elicit CTL response when immunized in HLA-A2.1/K^b^ transgenic mice. These epitopes could serve as candidates for TB subunit vaccines development.

Supplemental Information
========================

10.7717/peerj.1229/supp-1

###### Raw data

###### 

Click here for additional data file.

10.7717/peerj.1229/supp-2

###### Data of CTL lysis activity from PPD-donor

###### 

Click here for additional data file.

Additional Information and Declarations
=======================================

The authors declare there are no competing interests.

[Ming-xia Zhai](#author-1){ref-type="contrib"} performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

[Fei Chen](#author-2){ref-type="contrib"} performed the experiments, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

[Yuan-yuan Zhao](#author-3){ref-type="contrib"} performed the experiments, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

[Ya-hong Wu](#author-4){ref-type="contrib"} performed the experiments, reviewed drafts of the paper.

[Guo-dong Li](#author-5){ref-type="contrib"} analyzed the data, contributed reagents/materials/analysis tools, reviewed drafts of the paper.

[Yan-feng Gao](#author-6){ref-type="contrib"} conceived and designed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

[Yuan-ming Qi](#author-7){ref-type="contrib"} conceived and designed the experiments, contributed reagents/materials/analysis tools, wrote the paper, reviewed drafts of the paper.

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

1\. The Ethics Committee of Zhengzhou University.

2\. Statement: This project "Identification of CTL epitopes from drug-resistance related antigens of Mycobacterium tuberculosis" was reviewed and approved by the Ethics Committee of Zhengzhou University. The sample collection from healthy donors and animal experiment were according to the guidance of the Ethics Committee of Zhengzhou University (20120312, [Fig. S2](#supp-1){ref-type="supplementary-material"}).

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

1\. The Ethics Committee of Zhengzhou University.

2\. Statement: This project "Identification of CTL epitopes from drug-resistance related antigens of Mycobacterium tuberculosis" was reviewed and approved by the Ethics Committee of Zhengzhou University. The sample collection from healthy donors and animal experiment were according to the guidance of the Ethics Committee of Zhengzhou University (20120312, [Fig. S2](#supp-1){ref-type="supplementary-material"}).
